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A multicentre prospective cohort study assessing
the effectiveness of budesonide MMX
(CortimentMMX

) for active, mild-to-moderate
ulcerative colitis
Silvio Danese1,2, Ailsa Hart3, Axel Dignass4 , Gionata Fiorino1,2,
Edouard Louis5, Stefanos Bonovas1,2 , Geert D’Haens6, Iris Dotan7,
Gerhard Rogler8, Kristine Paridaens9 and Laurent Peyrin-Biroulet10
Abstract
Background: CortimentMMX

(budesonide MMX) is currently approved for the induction of remission in mild-to-moderate
ulcerative colitis (UC) patients when 5-ASA treatment is not sufficient. Data in real-life settings are lacking.
Methods: This was a multicentre observational prospective cohort study conducted in Europe and Canada. Effectiveness,
safety, and tolerability of CortimentMMX

in a real-life setting of patients treated for mild-to-moderate UC was investigated.
Patients were prescribed CortimentMMX

in accordance with the Summary of the Product Characteristics (SmPC).
The primary endpoint was the clinical benefit of Cortiment MMX in routine practice (improvement 3 points in the
clinical sub-scores of the Ulcerative Colitis Disease Activity Index, UCDAI).
Results: Data from 326 patients with mild-to-moderate UC were analysed for the primary endpoint. Clinical benefit was
achieved in 60.1% (196/326) of patients at the end of CortimentMMX

treatment. Clinical remission (UCDAI clinical sub-
score 1), full symptoms resolution (rectal bleeding (RB)¼ 0 and stool frequency (SF)¼ 0) and symptoms resolution
(RB¼ 0þ SF 1) at the end of the CortimentMMX treatment were achieved in 51.8%, 45.1% and 63.2% of patients,
respectively. The median time to symptoms resolution was 30 days (range 29.0–36.0 days). Fifty patients (14.3%) had to
discontinue CortimentMMX

due to adverse events; 17.5% of patients (n¼ 61) reported at least one adverse event related to
the study drug.
Conclusions: This was the first time that a large cohort study was conducted with CortimentMMX

in a real-life setting.
It demonstrated that CortimentMMX

is effective, safe and well tolerated in about 60% of UC patients.
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Key summary
Established knowledge on this subject
. Budesonide MMX is approved for the treatment of active mild-to-moderate ulcerative colitis;
. Budesonide MMX represents a valid and safer alternative to systemic steroids in patients with ulcerative
colitis who failed 5-ASA treatment;
. There are no large-scale real-life data showing the best therapeutic approach in patients with indication to
treatment with budesonide MMX (monotherapy vs. combination with 5-ASA).
What are the significant and/or new findings of this study?
. Our real-life data conﬁrm the eﬀectiveness and safety of budesonide MMX in patients with mild-to-
moderate active ulcerative colitis in terms of clinical beneﬁts and quality of life.
. Our data suggest that adding budesonide MMX to 5-ASA treatment might be the best therapeutic
approach to induce clinical remission compared to budesonide MMX monotherapy.
Introduction
Ulcerative colitis (UC) is a chronic inﬂammatory bowel
disease (IBD) that involves the colon and the rectum,
with continuous inﬂammation, erosions and/or ulcers
aﬀecting the colonic mucosa.1,4 Usually, the course
of the disease is characterised by ﬂares of active disease
with diarrhoea, rectal bleeding (RB) and rectal urgency,
alternating with periods of remission.2 The main
therapeutic goals to treat active ﬂares are the control
of symptoms, normalisation of bowel movements,
disappearance of bleeding and rectal urgency, com-
bined with the normalisation of inﬂammatory bio-
markers, such as C-reactive protein and/or faecal
calprotectin (FC), and the disappearance of mucosal
lesions.3,4
Systemic corticosteroids, such as prednisolone or
equivalents, are eﬀective therapies in active UC of
any severity, but their use is limited by their adverse
eﬀects.5 In order to minimise the side eﬀects of systemic
steroids, budesonide, a locally acting corticosteroid
with low bioavailability and little systemic absorption,
represents a valid alternative in IBD patients.6,7
However, the pH-dependent release mechanism of
budesonide may limit eﬀectiveness along the colonic
mucosa.8 In order to address this unmet need, a colonic
release system (MMX, Multi-Matrix System) that
provides targeted drug delivery to the entire colon has
been used successfully in conjunction with both mesa-
lazine and budesonide to allow a continuous and uni-
form release of the active principles along the colon.9–13
In the phase 2 trial, the ﬁrst data in patients with
left-sided UC showed that 47.1% of patients treated
with budesonide MMX 9mg once daily achieved clin-
ical remission compared to 33.0% of placebo-treated
patients.14 More recently, the CORE-II trial, a phase
3, randomised, double-blind, double-dummy, placebo-
controlled, parallel-group trial was conducted on 512
patients with active mild-to-moderate UC, mostly in
European countries.9 Patients were randomised
1:1:1:1 to receive budesonide MMX 9mg/day, bude-
sonide MMX 6mg/day, controlled ileal-release bude-
sonide 9mg/day once daily), or a placebo for 8weeks.9
Combined clinical and endoscopic remission at week 8
was achieved in 17.4% of patients treated with budeso-
nide MMX 9mg compared to 4.5% of patients in the
placebo group (p¼ 0.0047).9 As a secondary study
objective, more patients achieved histological healing
(16.5% vs. 6.7%, p¼ 0.036) and complete symptoms
resolution (23.9% vs. 11.2%, p¼ 0.022) when treated
with budesonide MMX 9mg compared with the pla-
cebo.9 Similar results were found in the CORE-I trial
conducted in the United States.15 In the pooled ana-
lysis, budesonide MMX safety and tolerability was
comparable to the placebo in terms of adverse events
(AEs) and mean cortisol serum levels.16
Currently, budesonide MMX 9mg/day is approved
for the induction of remission in patients with
mild-to-moderate UC where 5-ASA treatment is not
suﬃcient. The aim of this study was to evaluate the
eﬀectiveness and tolerability of budesonide MMX
(CortimentMMX

) in mild-to-moderate UC in a real-
life setting.
Methods
This was a multicentre observational prospective
cohort study conducted in IBD referral centres in
Poland, Italy, Germany, the United Kingdom, the
Netherlands, Sweden, Ireland and Canada. The main
aim of this study was to collect and analyse data
on the eﬀectiveness, safety and tolerability of
CortimentMMX

in a real-life setting of patients trea-
ted for mild-to-moderate UC.
Inclusion and exclusion criteria
Eligible patients were adult (aged 18 years), of either
gender, who had been prescribed CortimentMMX

for
the treatment of mild-to-moderate active UC within
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a 5-day window prior to being included in the study.
Exclusion criteria were severe active/fulminant UC, use
of concomitant antibiotics or systemic corticosteroids
for the current ﬂare, history of total/sub-total colec-
tomy, known hypersensitivity to the active substance
or to any of the excipients.
Study endpoints and outcome measures
Primary endpoint. The primary endpoint of this study
was to assess the clinical beneﬁt of CortimentMMX

in routine practice, deﬁned as the percentage of patients
achieving improvement 3 points in the clinical sub-
scores of the UCDAI (Ulcerative Colitis Disease
Activity Index) at the end of CortimentMMX

induc-
tion treatment.17
Secondary endpoints. Secondary eﬀectiveness endpoints
assessed at the end of CortimentMMX

induction treat-
ment were:
. the percentage of patients with clinical remission
deﬁned as UCDAI clinical sub-score 1;
. the percentage of patients with symptoms resolution
(RB¼ 0þ stool frequency (SF) 1, urgency¼ 0);
. the percentage of patients with full symptoms reso-
lution (RB¼ 0þSF¼ 0, urgency¼ 0);
. time to symptoms resolution (RB¼ 0, SF 1,
urgency¼ 0);
. the change in health-related quality of life (Short
Inﬂammatory Bowel Disease Questionnaire,
SIBDQ)18,19;
. the change in health economic parameters (Work
Productivity and Activity Impairment, WPAI)20;
. treatment satisfaction (Visual Analogue Scale)21,22;
. the percentage of patients with FC within normal
range (when FC tests were performed);
. the percentage of patients with endoscopic healing
(UCDAI endoscopic sub-score¼ 0); and
. the percentage of patient in remission (UCDAI
endoscopic sub-score 1) (when endoscopies
performed).
Additional study endpoints. As additional study end-
points, tolerability of CortimentMMX

in a real-life
setting (AEs) and adverse drug reactions (ADRs)
were assessed from 2 weeks up to 6 months after the
last CortimentMMX

dose for prolonged tapering oﬀ.
Moreover, to determine how CortimentMMX

is pre-
scribed and used by gastroenterologists in routine clin-
ical practice, the study evaluated the percentage of
patients given CortimentMMX

as monotherapy or as
an add-on therapy to 5-ASA and the relative time
frames, rates of CortimentMMX

treatment
discontinuation/end of treatment (rate, reason, time
frame, tapering oﬀ), and follow-up UC treatments
(5-ASA, corticosteroids, immunosuppressants or
biologics) were evaluated.
Safety. For safety analyses, AEs and concomitant dis-
eases were recorded, by assigned preferred terms (PTs)
and categorisation into the Primary System Organ
Class according to the MedDRA thesaurus version
20.1. Patients reporting more than one AE or concomi-
tant disease with the same PTs were counted once. The
AEs were reported as per national safety reporting
requirements.
Study time points. Eﬀectiveness was evaluated at the end
of CortimentMMX

induction treatment. The tolerabil-
ity and use of CortimentMMX

were assessed from
2 weeks up to a maximum of 6 months (in particular
circumstances) after the last CortimentMMX

dose.
Study groups. The primary endpoint, clinical beneﬁt,
(improvement 3 points in the UCDAI clinical sub-
scores at end of treatment) was compared between
three cohorts of patients. The cohorts were deﬁned as:
. CortimentMMX

added to 5-ASA at least 14 days
after increased/optimised 5-ASA dose for the treat-
ment of ﬂare (late add-on) (Cohort 1);
. CortimentMMX

added to 5-ASA within 14 days
since 5-ASA increased/optimised for the treatment
of ﬂare or without 5-ASA dose modiﬁcation (early
add-on) (Cohort 2); and
. CortimentMMX

as monotherapy for the treatment
of ﬂare (mono) (Cohort 3).
Statistical analyses
Descriptive statistics were used to analyse the study data.
Continuous variables were summarised using the
number of patients, mean, standard deviation, min-
imum, ﬁrst quartile, median, third quartile and max-
imum. For categorical variables, data were summarised
by the number and percentage of patients in each cat-
egory; 95% conﬁdence intervals (CIs) were provided to
evaluate the level of precision of the calculated estimates.
Incidence percentages were calculated as follows:
number of patients with one or more occurrences of
the item divided by the number of patients in the ana-
lysis set, times 100.
Missing data were not imputed. When summarising
categorical variables, in case of any missing responses,
these were shown as a separate category. For continu-
ous variables, the number of non-missing observations
was displayed.
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All discontinuations after enrolment were sum-
marised by time of, and reason for, discontinuation.
Tests were carried out with a two-sided signiﬁcance
level of 0.05. CIs were set at 95%.
The association between the explanatory clinical
variables and the outcome (response) variable was
tested in univariable analyses with the chi-square test.
Then, all selected variables (using p< 0.20 as selection
criterion) were included in the multivariable logistic
regression analysis, and a backwards stepwise selection
process was followed.23 Odds ratios with 95% CIs
derived from the ﬁnal multivariable logistic regression
model are presented.
No formal hypothesis was tested in this observa-
tional, prospective cohort study. All enrolled patients
who received at least one dose of CortimentMMX

and
met the inclusion or exclusion criteria were included in
the analyses.
The estimated sample size was 350 patients.23
In order to perform a comparison among the three
cohorts, patients were matched to adjust for the eﬀects
of covariates. Matching was based on the propensity
score method. The following covariates were con-
sidered for the calculation of the propensity score:
gender (male, female), age (18–34; 35–59; 60þ years),
number of UC ﬂares in the last year, baseline extension
of disease, baseline endoscopic sub-score, baseline score
for stool frequency during the last 3 days, baseline score
for RB during the last 3 days, baseline response for
urgency episodes during the last week, baseline UC-
related extra-intestinal symptoms during the last
week, Physician’s Global Assessment at baseline. The
propensity score was calculated by means of a multi-
variable logistic regression analysis. The absolute dif-
ference among cohorts’ patients’ matched propensity
scores was set to 0.01.
Ethical considerations
This study was conducted according to the 1975
Declaration of Helsinki and the European Medicines
Agency Guidelines for Good Clinical Practice. All eth-
ical review boards from each participating centre
approved this study. This study was registered on clin-
icaltrials.gov (ClinicalTrials.gov Identiﬁer:
NCT02586259). Written, informed consent was
obtained from each patient included in the study
prior to the start of any study procedure.
Results
Study population
A total of 378 patients from eight countries were screened
(Poland, Italy, Germany, the United Kingdom, the
Netherlands, Sweden, Ireland and Canada); 349 evalu-
able patients, who had been prescribed
CortimentMMX

for the treatment of mild-to-moder-
ate active UC, within a 5-day window, were included in
the study. The major protocol deviations consisted of
no CortimentMMX

treatment and inclusion/exclusion
criteria not satisﬁed. Baseline characteristics are sum-
marised in Table 1. Of these 349 patients, 23 were lost
at follow-up after Visit 1 and therefore were excluded
from the primary endpoint analysis.
Effectiveness on symptoms
In the entire study population, 196 patients (60.1%)
achieved clinical beneﬁt (reduction of 3 points in the
UCDAI clinical sub-score) at the end of treatment
(64.3%, 62.1%, and 33.3% in cohorts 1, 2 and 3
respectively), with a median drop of 3.0 UCDAI
points (p¼ 0.0096) (Table 2). At the end of treatment,
the median UCDAI score dropped from 5.0 to 1.0 in
the overall cohort (5.0 to 1.0 in cohorts 1 and 2, 4.0 to
2.0 in Cohort 3) compared to baseline.
Clinical remission, deﬁned as UCDAI clinical sub-
score 1, was achieved in 169 (51.8%) patients in the
overall evaluable set (57.1%, 52.7% and 33.3% patients
in cohorts 1, 2 and 3 respectively) (Table 2).
Full resolution of symptoms at the end of the
CortimentMMX

treatment, deﬁned as the absence of
rectal bleeding (RB¼ 0), normalisation of bowel habit
(SF¼ 0) and no urgency was achieved in 147 patients
(45.1%) (51.8%, 45.3% and 29.6% in cohorts 1, 2 and
3 respectively). Symptoms resolution (RB¼ 0, SF 1
and no urgency) was achieved in 206 (63.2%) patients
from the entire study population (71.4%, 63.0%, and
48.1% in the three cohorts, respectively). The median
time to symptoms resolution was 30 days (range
29.0–36.0 days) (Table 2).
After propensity score matching, the overall diﬀer-
ence was statistically signiﬁcant for clinical beneﬁt
(p¼ 0.0101), clinical remission (p¼ 0.0216) and symp-
toms resolution (p¼ 0.0366), whereas it was not statis-
tically signiﬁcant for full symptoms resolution
(p¼ 0.0752).
Effectiveness on objective signs of inflammation
Data about objective measures of inﬂammation, such
as FC and endoscopy, at baseline and at the end of
induction were available for 14 and 32 patients, respect-
ively. Due to the small number of patients who under-
went dosing of FC at both baseline and end of
CortimentMMX

induction treatment, no clear ten-
dency can be drawn. Mucosal healing (deﬁned as a
Mayo endoscopic sub-score equal to 0) was achieved
in 5/32 patients (15.6%) at the end of treatment,
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whereas endoscopic remission (Mayo endoscopic sub-
score 1) was achieved in 16/32 patients (50.0%).
Patient-reported outcomes. The median increase in the
SIBDQ was 10.0 points for the whole cohort compared
to baseline assessment (p< 0.001). Improvement in
quality of life was observed in all three cohorts
(median SIBDQ increase of 11.0, 14.0 and 7.0 respect-
ively) with a signiﬁcant improvement in quality of life
(p< 0.001) only in cohorts 1 and 2 (Figure 1).
Additionally, patient satisfaction of CortimentMMX

treatment was high (Visual Analogue Scale (VAS)
scale: rating of 7- to 10/10) in 61.3% of patients, with
similar rates in the three cohorts (71.3%, 60.4% and
60.4% respectively).
Regarding work productivity, the mean percent
work time missed due to ill health, the mean percent
impairment while working due to ill health and the
mean percent overall work impairment due to ill
health were all reduced in the whole population by
8.9%, 21.3% and 23.7% respectively (p< 0.0001 in
both the paired t-test and the non-parametric signed
rank sum test for all variables, Figure 1).
Predictors of clinical benefit
Baseline RB (p< 0.0001), Physician’s Global
Assessment (p< 0.0001), compliance to
CortimentMMX

treatment during induction phase
(p¼ 0.0002), country (p< 0.0001), age (p¼ 0.0469),
Table 1. Baseline characteristics of the study population.
Variable
Cohort 1
(n¼ 59)
Cohort 2
(n¼ 260)
Cohort 3
(n¼ 30)
Total
(N¼ 349)
Gender (N (%))
Females 36 (61.0%) 132 (50.8%) 15 (50.0%) 183 (52.4%)
Age (years, median) 45.0 39.0 42.5 40.0
Smoking status (N (%))
Current smoker 2 (3.4%) 12 (4.6%) 0 (0%) 14 (4.0%)
Former Smoker 17 (28.8%) 40(15.4%) 8 (26.7%) 65 (18.6%)
Non-smoker 40 (67.8%) 208 (80.0%) 22 (73.3%) 270 (77.4%)
Maximal extension of UC in the past (N (%))
Proctitis 6 (10.2%) 24 (9.2%) 1 (3.3%) 31 (8.9%)
Proctosigmoiditis 7 (11.9%) 34 (13.1%) 6 (20.0%) 47 (13.5%)
Left-sided Colitis 30 (50.8%) 104 (40.0%) 8 (26.7%) 142 (40.7%)
Pancolitis 12 (20.3%) 87 (33.5%) 13 (43.3%) 112 (32.1%)
Unknown 4 (6.8%) 11 (4.2%) 2 (6.7%) 17 (4.9%)
Median UCDAI score 5.0 5.0 4.0 5.0
Mean UCDAI score (SD) 5.0 (1.7) 5.2 (1.5) 4.3 (1.8) 5.0 (1.7)
Last oral corticosteroid (N (%))
None 38 (64.4%) 165 (63.5%) 21 (70.0%) 224 (64.2%)
Prednisone or prednisolone 18 (30.5%) 74 (28.5%) 9 (30.0%) 101 (28.9%)
Budesonide MMX 1 (1.7%) 7 (2.7%) 1 (0%) 8 (2.3%)
Beclomethasone
Betamethasone
0 (0%)
0 (0%)
6 (2.3%)
0 (0%)
0 (0%)
0 (0%)
6 (1.7%)
1 (0%)
Budesonide 0 (0%) 2 (0.8%) 0 (0%) 2 (0.6%)
Other 2 (3.4%) 6 (2.3%) 0 (0%) 8 (2.3%)
History of immunosuppressants (N (%))
Yes 13 (22.0%) 77 (29.6%) 8 (26.7%) 98 (28.1%)
No 46 (78.0%) 176 (67.7%) 20 (66.7%) 242 (69.3%)
Unknown 0 (0%) 7 (2.7%) 2 (6.7%) 9 (2.6%)
History of biologics (N (%))
Yes 2 (3.4%) 29 (11.2%) 5 (16.7%) 36 (10.3%)
No 56 (94.9%) 224 (86.2%) 24 (80.0%) 304 (87.1%)
Unknown 1 (1.7%) 7 (2.7%) 1 (3.3%) 9 (2.6%)
UC: ulcerative colitis; UCDAI: Ulcerative Colitis Disease Activity Index; SD: standard deviation
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smoking history (p¼ 0.0351), baseline urgency episodes
(p¼ 0.0012), cohort (p¼ 0.0117), number of UC ﬂares
in the last year (p¼ 0.0205), and number of oral 5-ASA
induction courses in the last year (p¼ 0.0013) were
selected for analysis in the multivariable model. In the
multivariable analysis with logistic regression, baseline
RB (streaks/obvious/blood alone vs. none), Physician’s
Global Assessment (moderate/severe vs. normal/mild),
compliance to CortimentMMX

treatment (80% vs.
<80%) and country (Poland vs. other countries) were
independently associated with a higher probability of
achieving clinical beneﬁt from budesonide MMX
(Table 3).
Safety
In the overall population, 24.1% (n¼ 84) of patients
reported at least one AE. Sixty patients (17.5%)
reported at least one AE related to the study drug; 50
patients (14.3%) had to discontinue budesonide
MMX due to AEs; in two patients (0.6%) ADRs
were recorded as serious and two (0.6%) as severe.
No deaths were reported during the study period. The
most common AEs reported were drug ineﬀectiveness
for 12% of patients (n¼ 43), product use issues for 5%
of patients (n¼ 16), and gastrointestinal disorders for
3% of patients (n¼ 9). All other AEs were reported in
<1.0% of patients (Table 4).
Table 2. Clinical effectiveness endpoints at the end of treatment.
Cohort 1
(n¼ 59)
Cohort 2
(n¼ 260)
Cohort 3
(n¼ 30)
Total
(N¼ 349)
Clinical benefit
(3 point reduction UCDAI clinical sub-score)
N (%) 36 (64.3%) 151 (62.1%) 9 (33.3%) 196 (60.1%)
[95% CI] [50.4–76.6] [55.7–68.3] [16.5–54.0] [54.6–65.5]
Clinical remission
(UCDAI clinical sub-score 1)
N (%) 32 (57.1%) 128 (52.7%) 9 (33.3%) 169 (51.8%)
[95% CI] [43.2–70.3] [46.2–59.1] [16.5–54.0] [46.3–57.4]
Symptoms resolution
(RB¼ 0þ SF 1 and no urgency)
N (%) 40 (71.4%) 153 (63.0%) 13 (48.1%) 206 (63.2%)
[95% CI] [57.8–82.7] [56.6–69.0] [28.7–68.1] [57.7–68.4]
Full symptoms resolution
(RB¼ 0þ SF¼ 0 and no urgency)
N (%) 29 (51.8%) 110 (45.3%) 8 (29.6%) 147 (45.1%)
[95% CI] [38.0–65.3] [38.9–51.8] [13.8–50.2] [39.6–50.7]
UC status N (%)
No response/relapse 22 (12.2%) 11 (15.9%) 3 (14.3%) 36 (13.3%)
Partial response 54 (29.8%) 19 (27.5%) 4 (19.0%) 77 (28.4%)
Complete response 105 (58.0%) 39 (56.5%) 14 (66.7%) 158 (58.3%)
UCDAI¼Ulcerative Colitis Disease Activity Index
Baseline
Cohort 1 Cohort 2
End of induction
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Figure 1. Median improvement of quality of life (SIBDQ scores)
and decrease of work impairment scores (WPAI) compared to
baseline among the study cohorts and in the overall populations.
Table 3. Final multivariable logistic regression model for
predictors of clinical benefit in the study cohort.
Variable
Odds
ratio 95% CI p-value
Presence of baseline rectal
bleeding
3.443 1.786–6.637 <0.001
Physician’s Global Assessment 2.642 1.547–4.512 <0.001
Compliance to CortimentMMX

treatment during induction
phase >¼ 80%
2.693 1.459–4.971 0.001
Country: Poland 2.382 1.393–4.071 0.001
95% CI¼ 95% confidence interval
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Prescribing patterns
The study showed that CortimentMMX

was mainly
prescribed as an add-on therapy to 5-ASA (91.4% vs.
8.6% as monotherapy). In this patient population,
5-ASA dose was optimised before CortimentMMX

induction treatment in 41.0% of patients (143). The
5-ASA dose optimisation was performed within
14 days for 24.1% (84) of patients with a median time
of 0.0 days (95% CI [29.0, 53.0]), and after a minimum
of 14 days for 16.9% (59) of patients with a median
time of 43 days (95% CI [0.0, 1.0]).
At the end of CortimentMMX

induction treatment,
CortimentMMX

treatment was stopped for the major-
ity of patients (83.8%, n¼ 274) and was modiﬁed
for tapering in 16.2% (53) of patients. The majority
of patients with tapering were taking 9mg/day of
CortimentMMX

every 2 days (77.4%, n¼ 41).
The median duration of CortimentMMX

treatment
was 57.0 days. The mean (standard deviation, SD) time
from the end of CortimentMMX

induction treatment
to follow-up visit was 29.3 (24.8) days, and was per-
formed in 270 (77.4%) patients. The most common
UC treatment at follow-up was oral 5-ASA, which
was taken by 230 patients (85.2% of patients partici-
pated in the follow-up assessment), whereas systemic
corticosteroids were taken by 38 (14.1%) patients, bio-
logical drugs were taken by 21 (7.8%) patients and
immunosuppressants were taken by 32 (11.9%)
patients.
Discussion
Budesonide MMX is currently approved in Europe
for the treatment of active mild-to-moderate UC, for
patients refractory or intolerant to mesalazine. Data
from the CORE trials8,15,18 showed that one-third
of patients receiving CortimentMMX

9mg/day for
8 weeks as monotherapy achieved clinical improvement
(reduction of 3 points in UCDAI sub-score), and
about one-quarter achieved full symptoms resolution
(RB¼ 0þ SF¼ 0). However, data from real-life clinical
practice were lacking.
Our cohort study included 349 patients who had
been prescribed CortimentMMX

by their treating
physician according to the local SmPC, and independ-
ently of their participation in the study. Of these
patients, 23 were lost at follow-up before Visit 2, and
were therefore excluded from the primary endpoint
analysis. When CortimentMMX

was used as an add-
on to 5-ASA therapy, we found that 64.3% (Cohort 1)
and 62.1% (Cohort 2) of patients achieved clinical
beneﬁt (improvement 3 points in the UCDAI clinical
sub-score) with no diﬀerences in the timing of admin-
istration (less or more than 14 days since 5-ASA was
started). Moreover, in both add-on cohorts, 51.8%
(Cohort 1) and 45.3% (Cohort 2) of patients achieved
full symptoms resolution, deﬁned as the absence of RB,
normalisation of bowel habits and no urgency, com-
pared to 29.6% receiving CortimentMMX

as mono-
therapy (Cohort 3). Absence of RB and normalisation
of bowel habits are currently considered as the most
valuable patient-reported outcomes in evaluating treat-
ment success in UC.5 The time to symptoms resolution
(RB¼ 0þ SF 1) ranged from 29 to 36 days.
Outcomes related to a patient’s daily life were improved
signiﬁcantly following CortimentMMX

treatment.
Health-related quality of life measures (according to
the SIBDQ) increased and WPAI scores reduced.
Moreover, CortimentMMX

treatment satisfaction, as
reported by the patients, was generally high. These data
might suggest that there is greater beneﬁt from being
treated with CortimentMMX

in combination with
5-ASA compounds rather than as a monotherapy.
Regarding the objective signs of inﬂammation,
the number of patients where data were available
both at baseline and end of treatment was small.
Thus, no clear conclusion on the eﬀect of
Table 4. Patients with adverse events.
Variable (N (%))
Cohort 1
(n¼ 59)
Cohort 2
(n¼ 260)
Cohort 3
(n¼ 30)
Total
(n¼ 349)
Number of patients with at least one AE 9 (15.3%) 68 (26.2%) 7 (23.3%) 84 (24.1%)
Number of deaths 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Number of patients with at least one serious AE 0 (0.0%) 7 (2.7%) 0 (0.0%) 7 (2.0%)
Number of patients with at least one
AE leading to discontinuation
6 (10.2%) 40 (15.4%) 4 (13.3%) 50 (14.3%)
Number of patients with at least one severe AE 0 (0.0%) 6 (2.3%) 0 (0.0%) 6 (1.7%)
Number of patients with at least one ADR 9 (15.3%) 46 (17.7%) 6 (20.0%) 61 (17.5%)
Number of patients with at least one serious ADR 0 (0.0%) 2 (0.8%) 0 (0.0%) 2 (0.6%)
Number of patients with at least one severe ADR 0 (0.0%) 2 (0.8%) 0 (0.0%) 2 (0.6%)
AE¼ adverse event; ADR¼ adverse drug reaction.
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CortimentMMX

treatment on endoscopic appearance
and FC levels can be given.
Baseline RB, baseline Physician’s Global
Assessment, compliance with the treatment during
induction 80% and being treated in Poland were fac-
tors associated with a higher probability of responding
to budesonide MMX.
Budesonide was well tolerated, with 24.0% of patients
reporting at least one AE, compared to 56.5% of patients
in the CORE pooled analysis. No major AEs that are
usually seen with systemic steroids were observed, and
the most common AEs related to drug ineﬃcacy, gastro-
intestinal disorders or product use issues. These data con-
ﬁrm that budesonide MMX acts locally with negligible
systemic eﬀects and can be considered a safe drug in the
mild-to-moderate UC population.
Our study has some limitations. First, there was a
diﬀerent proportion of patients enrolled in the add-on
cohorts, 1 and 2, compared to Cohort 3 (monotherapy).
Patients were not stratiﬁed for strategy chosen, how-
ever, our cohort was large enough to capture signiﬁcant
diﬀerences among the cohorts and our data are not
diﬀerent from previous Randomized Controlled Trial
(RCT) data,8,15,18 supporting the validity of our results.
Second, the diﬀerence in response rates among coun-
tries (i.e. Poland vs. other countries) reﬂects the hetero-
geneity of the study population, which may have had
an impact on these ﬁndings (Polish patients represent
51.2% of the population). However, this is expected in
a real-life cohort, which usually enrols patients that are
diﬀerent from RCT study populations.8,15,18 Third,
data on objective measures of inﬂammation are limited,
as few patients underwent endoscopies and FC tests at
both baseline and end of CortimentMMX

treatment.
However, this study has also several strengths. This
is the largest real-life cohort study in mild-to-moderate
UC patients treated with CortimentMMX

, who were
mainly treated in third-level referral centres with experi-
enced IBD clinicians. Our ﬁndings demonstrate good
eﬀectiveness in real-life practice and help to understand
the best patient proﬁle and the best strategies to adopt
for the use of CortimentMMX

in daily practice. The
cohort aﬃliation of patients also indicated that in
about half of the cases, 5-ASA dose optimisation is
not carried out according to mild-to-moderate UC
treatment guidelines.6
In conclusion, in this large real-life UC cohort,
CortimentMMX

was conﬁrmed to be eﬀective, safe
and well tolerated.
Acknowledgments
Ferring and the authors would like to thank all study inves-
tigators and their teams for their contributions. (Participating
sites and principal study investigators listing in the
Appendix.) The principal investigators in this study were
Ardizzone Sandro, Astegiano Marco, Augustyn Monika,
Baluta Malgorzata, Barczyk Wojciech, Bendia Emanuele,
Binkowska-Borgosz Izabela, Blaszczyn´ska Malgorzata,
Bresso Francesca, Brymora Malgorzata, Castiglione
Fabiana, Comberlato Michele, Cosintino Rocco, Costa
Francesco, Detka-Kowalska Iga, Drobin´ska Anna,
Dudkowiak Robert, Eberhardson Michael, Fraczek
Grzegorz, Geccherle Andrea, Gionchetti Paolo, Halfvarson
Jonas, Hayee Bu, Hertervig Erik, Hjortswang Henrik,
Janiak Maria, Jansen Jeroen, Jasin´ski Boleslaw, Jastrzebska
Marta, Jessen Petra, Jonas Maurycy, Kaczmarzyk Pawel,
Kaniewska Magdalena, Kedzierska Lidia, Kempin´ski
Radoslaw, Klincewicz Beata, Klugmann Tobias, Kosik-
Warzyn´ska Romana, Krause Thomas, Krawczyk Marek,
Krela-Kaz´mierczak Iwona, Lapin´ski Janusz, Latos
Wojciech, Lykowska-Szuber Liliana, Maciejewska
Katarzyna, Majowski Jaroslaw, Malewski Waldemar,
Maluch Piotr, Mamos Arkadiusz, Manerowski Marcin,
Markowski Adam, Mazurek Tadusz, Miehlke Stefan,
Mowat Craig, Mularczyk Aldona, Mulcahy Hugh,
Nijhawan Pardep, Orlando Ambrogio, Orlowski Marcin,
Pastorelli Luca, Penpicki Andrzej, Pilecka Dorota,
Piotrowski Wojciech, Prasad Neeraj, Reddy Jagan, Rocca
Rodolfo, Romatowski Jacek, Rydzewska Graz_yna, Sangfelt
Per, Schubert Stefan, Seenan John Paul, Selinger Christian,
Singh Andrew, Stro´zik Agnieszka, S´wiatkowski Tomasz,
Tomecki Roman, Walentek Tomasz, Was´ko-Czopnik
Dorota, West Rachel, Wierzbicka Katarzyna, Wis´niewska
Jarosin´s´ka Maria, Wis´niowski Marek, Wojnarowska
Renata, Wo´jtowicz Henryk, Wontor-Buksin´ska Aleksandra,
Worobiec Jacek and Wyszkowski Mariusz.
Conflict of interest
The authors declared the following potential conﬂicts of inter-
est with respect to the research, authorship, and/or publica-
tion of this article: SD has served as a speaker, consultant and
advisory board member for Schering-Plough, Abbott
(AbbVie) Laboratories, Merck and Co, UCB Pharma,
Ferring, Cellerix, Millenium Takeda, Nycomed,
Pharmacosmos, Actelion, a Wasserman, Genentech,
Grunenthal, Pﬁzer, Astra Zeneca, Novo Nordisk, Cosmo
Pharmaceuticals, Vifor, and Johnson and Johnson. AH has
lectured/been on advisory boards for Atlantic, BMS, Falk
Pharma, MSD, AbbVie, Takeda, Hospira, Napp
Pharmaceuticals, Ferring, Yakult, Pﬁzer, Janssen, Warner
Chillcott, and Genentech. AD has served as a speaker and
consultant for Ferring, Falk Pharma, Mundipharma,
Hospira, Sandoz, Otsuka, AbbVie, Janssen, Takeda, MSD,
Vifor, and Pharmacosmos. GF received consultancy fees
from Ferring, MSD, AbbVie, Takeda, Janssen, Amgen,
Sandoz, Samsung Bioepis, Celltrion. EL has received fees
for: Educational Grant: fees for Educational activities paid
by the Company, MSD, AbbVie; speaker fees: AbbVie,
Ferring, MSD, Chiesi, Mitsubishi Pharma, Hospira,
Janssen, Takeda; serving on an advisory board: AbbVie,
Ferring, MSD, Takeda, Mitsubishi Pharma, Celltrion,
Prometheus. BS is supported by FIRMAD and has served
as advisor for Ferring. GD’H has served as advisor for
AbbVie, Ablynx, Amakem, AM Pharma, Avaxia, Biogen,
1178 United European Gastroenterology Journal 7(9)
Bristol Meiers Squibb, Boerhinger Ingelheim, Celgene,
Celltrion, Cosmo, Covidien, Ferring, DrFALK Pharma,
Engene, Ferring, Galapagos, Gilead, Glaxo Smith Kline,
Hospira, Johnson and Johnson, Medimetrics, Millenium/
Takeda, Mitsubishi Pharma, Merck Sharp Dome,
Mundipharma, Novonordisk, Pﬁzer, Prometheus labora-
tories/Nestle, Receptos, Robarts Clinical Trials, Salix,
Sandoz, Setpoint, Shire, Teva, Tigenix, Tillotts, Topivert,
Versant and Vifor, and received speaker fees from AbbVie,
Ferring, Johnson and Johnson, MSD, Mundipharma,
Norgine, Pﬁzer, Shire, Millenium/Takeda, Tillotts, and
Vifor. ID has served as a speaker and/or consultant for
Ferring, Falk Pharma, Rafa laboratories, AbbVie, Janssen,
Takeda, Genentech, Pﬁzer, Protalix, Arena, Gilead, Celltrion,
MSD, and Given Imaging. GR has served as a speaker and
consultant for AbbVie, Ardeypharm, AstraZeneca,
Boehringer, Celgene, Ferring, Falk Pharma, Genentech,
Janssen, Novartis, Merck, MSD, Pﬁzer, Pharmabiome,
Roche, Takeda, Tillots, UCB, Vital Solutions, and Vifor,
Zeller.KP is an employee of Ferring. LPB has received con-
sulting fees from Merck, AbbVie, Janssen, Genentech,
Mitsubishi, Ferring, Norgine, Tillots, Vifor, Therakos,
Pharmacosmos, Pile`ge, BMS, UCB Pharma, Hospira,
Celltrion, Takeda, Biogaran, Boerhinger Ingelheim, Lilly,
Pﬁzer, HAC-Pharma, Index Pharmaceuticals, Amgen, and
Sandoz; and lecture fees from Merck, AbbVie, Takeda,
Janssen, Takeda, Ferring, Norgine, Tillots, Vifor, Therakos,
Mitsubishi, and HAC-Pharma.
Funding
Ferring Pharmaceuticals funded the study and participated in
the study design, interpretation of data, review, and approval
of the publication.
Ethics approval
The ﬁrst Ethical Committee approval has been obtained on
22/12/2015 in Ethikkommission der A¨rztekammer Hamburg,
Germany. Then, the protocol was approved as follows:
Ireland 25/10/2016 Ethics and Medical Research Committee
The Netherlands 26/09/2016 ACWO OLVG (Notiﬁcation
only) Sweden 08/06/2016 Regionala etikpro¨vningsna¨mnden i
Stockholm Canada 05/12/2016 IRB Services Italia 13/12/2016
Comitato Etico Azienda Ospedaliera Universitaria Policlinico
‘‘Sant’Orsola – Malpighi Great Britain 20/07/2017 South East
Scotland Research Ethics Committee Poland 18/03/2016
Komisja Bioetyczna Okregowej Izby Lekarskie (Notiﬁcation
only).
Informed consent
An informed consent form in the patients’ native language
was used. Two versions of the informed consent form were
reviewed and approved by the local Ethical Committees, and
used during the study (version 1.0, Sep 8th, 2015, and version
2.0, July 4th, 2017).
ORCID iD
Axel Dignass https://orcid.org/0000-0002-9724-054X
Stefanos Bonovas https://orcid.org/0000-0001-6102-6579
References
1. Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med
2011; 365: 1713–1725.
2. Solberg IC, Lygren I, Jahnsen J, et al. Clinical course
during the first 10 years of ulcerative colitis: results
from a population-based inception cohort (IBSEN
Study). Scand J Gastroenterol 2009; 44: 431–440.
3. Peyrin-Biroulet L, Sandborn W, Sands BE, et al.
Selecting therapeutic targets in inflammatory bowel dis-
ease (STRIDE): determining therapeutic goals for treat-
to-target. Am J Gastroenterol 2015; 110: 1324–1338.
4. Magro F, Gionchetti P, Eliakim R, et al. Third European
evidence-based consensus on diagnosis and management
of ulcerative colitis. Part 1: definitions, diagnosis, extra-
intestinal manifestations, pregnancy, cancer surveillance,
surgery, and ileo-anal pouch disorders. J Crohns Colitis
2017; 11: 649–670.
5. Harbord M, Eliakim R, Bettenworth D, et al. Third
European evidence-based consensus on diagnosis and
management of ulcerative colitis. Part 2: current manage-
ment. J Crohns Colitis 2017; 11: 769–784.
6. Bonovas S, Nikolopoulos GK, Lytras T, et al.
Comparative safety of systemic and low-bioavailability
steroids in inflammatory bowel disease: systematic
review and network meta-analysis. Br J Clin Pharmacol
2018; 84: 239–251.
7. Gomollo´n F, Dignass A, Annese V, et al. 3rd European
evidence-based consensus on the diagnosis and manage-
ment of Crohn’s disease 2016. Part 1: diagnosis and med-
ical management. J Crohns Colitis 2017; 11: 3–25.
8. Travis SPL, Danese S, Kupcinskas L, et al. Once-daily
budesonide MMX in active, mild-to-moderate ulcerative
colitis: results from the randomised CORE II study. Gut
2014; 63(3): 433–441.
9. Brunner M, Ziegler S, Di Stefano AF, et al.
Gastrointestinal transit, release and plasma pharmaco-
kinetics of a new oral budesonide formulation. Br J
Clin Pharmacol 2006; 61: 31–38.
10. McCormack PL, Robinson DM and Perry CM. Delayed-
release Multi Matrix System (MMX) mesalazine: in
ulcerative colitis. Drugs 2007; 67: 2635–2642.
11. Nicholls A, Harris-Collazo R, Huang M, et al.
Bioavailability profile of Uceris MMX extended-release
tablets compared with Entocort EC capsules in healthy
volunteers. Journal Int Med Res 2013; 41: 386–394.
12. Prantera C, Viscido A, Biancone L, et al. A new oral
delivery system for 5-ASA: preliminary clinical findings
for MMx. Inflamm Bowel Dis 2005; 11: 421–427.
13. Tenjarla S, Romasanta V, Zeijdner E, et al. Release of
5-aminosalicylate from an MMX mesalamine tablet
during transit through a simulated gastrointestinal tract
system. Adv Ther 2007; 24: 826–840.
14. D’Haens GR, Kovacs A, Vergauwe P, et al. Clinical trial:
preliminary efficacy and safety study of a new
Budesonide-MMX(R) 9mg extended-release tablets in
patients with active left-sided ulcerative colitis. J Crohns
Colitis 2010; 4: 153–160.
15. Sandborn WJ, Travis S, Moro L, et al. Once-daily bude-
sonide MMX(R) extended-release tablets induce
Danese et al. 1179
remission in patients with mild to moderate ulcerative
colitis: results from the CORE I study. Gastroenterology
2012; 143: 1218–1226.
16. Lichtenstein GR, Travis S, Danese S, et al. Budesonide
MMX for the induction of remission of mild to moderate
ulcerative colitis: a pooled safety analysis. J Crohns
Colitis 2015; 9: 738–746.
17. Ma C, Panaccione R, Fedorak RN, et al. Heterogeneity
in definitions of endpoints for clinical trials of ulcerative
colitis: a systematic review for development of a core out-
come set. Clin Gastroenterol Hepatol 2018; 16: 637–647.
18. Irvine EJ, Zhou Q, Thompson AK The Short
Inflammatory Bowel Disease Questionnaire: a quality
of life instrument for community physicians managing
inflammatory bowel disease. CCRPT Investigators.
Canadian Crohn s Relapse Prevention Trial. Am J
Gastroenterol 1996; 91(8): 1571–1578.
19. Han SW, Gregory W, Nylander D, et al. The SIBDQ:
Further validation in ulcerative colitis patients. The
American Journal of Gastroenterology 2000; 95(1): 145–
151.
20. Jowett SL, Seal CJ, Barton JR, et al. The short inflam-
matory bowel disease questionnaire is reliable and
responsive to clinically important change in ulcerative
colitis. The American Journal of Gastroenterology 2001;
96(10): 2921–2928.
21. Reilly MC, Zbrozek AS, & Dukes E. The validity and
reproducibility of a work productivity and activity impair-
ment instrument.Pharmaco Economics 1993; 4(5): 353–365.
22. de Boer AG, van Lanschot JJ, Stalmeier PF, et al. Is a
single-item visual analogue scale as valid, reliable and
responsive as multi-item scales in measuring quality of
life? Quality of Life Research 2004; 13(2): 311–320.
23. Brokelman RBG, Haverkamp D, et al. The validation of
the visual analogue scale for patient satisfaction after
total hip arthroplasty. Eur Orthop Traumatol 2012; 3:
101–105.
Appendix: Participating sites listing
Country Principal investigator Institution name City
Canada Nijhawan, Pardep Digestive Health Clinic Richmond Hill
Reddy, Jagan Sudbury Endoscopy Centre Sudbury
Singh, Andrew PerCuro Clinical Research Victoria
Germany Miehlke, Stefan Magen-Darm-Zentrum, Facharztzentrum
Eppendorf
Hamburg
Krause, Thomas Gastroenterologie Opernstraße Kassel
Schubert, Stefan Gastroenterologie am Bayerischen Platz Berlin
Klugmann, Tobias Internistische Gemeinschaftspraxis Leipzig
Jessen, Petra Gemeinschaftspraxis Altenholz
United Kingdom Prasad, Neeraj Royal Albert Edward Infirmary Wigan
Hayee, Bu Kings College Hospital London
Selinger, Christian St. James’s University Hospital Leeds
Seenan, John Paul Queen Elizabeth University Hospital Glasgow
Mowat, Craig Tayside University Hospitals NHS Trust, Ninewells
Hospital and Medical School
Dundee
Ireland Mulcahy, Hugh St. Vincent’s University Hospital Dublin
Italy Gionchetti, Paolo A.O.U. Policlinico S. Orsola Malpighi Bologna
Pastorelli, Luca Policlinico S. Donato San Donato Milanese
Astegiano, Marco A.O.U. Citta` della Salute e della Scienza Torino
Rocca, Rodolfo A.O. Ordine Mauriziano P.O. Umberto I Torino
Cosintino, Rocco A.O. San Camillo Forlanini Roma
Orlando, Ambrogio A.O. Ospedali Riuniti Villa Sofia - Cervello Palermo
Castiglione, Fabiana A.O.U. Federico II Napoli
Geccherle, Andrea A.O. Ospedale Sacro Cuore Don Calabria Negrar
Bendia, Emanuele A.O.U. Ospedali Riuniti Umberto I, G.M. Lancisi, G.
Salesi
Ancona
Comberlato, Michele A.S.A.A. Ospedale di Bolzano Bolzano
Costa, Francesco A.O.U. Pisana Presidio di Cisanello Pisa
Ardizzone, Sandro A.S.S.T. Fatebenefratelli Sacco Milano
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Country Principal investigator Institution name City
Netherlands Jansen, Jeroen OLVG – Oost Amsterdam
West, Rachel Fransiscus Gasthuis Rotterdam
Poland Wis´niewska Jarosin´s´ka, Maria Centrum Medyczne S´w Rodziny Poradnia
Gastrologiczna
Ło´dz´
Brymora, Małgorzata Poradnia Gastroenterologiczna-Szpital
Uniwersytecki nr 2
Bydgoszcz
Manerowski, Marcin Poradnia Choro´b Jelitowych-Szpital Uniwersytecki
nr 2
Bydgoszcz
Błaszczyn´ska, Małgorzata SP ZOZ ZESPO´Ł SZPITALI MIEJSKICH Chorzo´w
Binkowska-Borgosz, Izabela SPSK 1 PUM w Szczecinie Szczecin
Wontor-Buksin´ska, Aleksandra Indywidualna Praktyka Gastrologiczna Cze˛stochowa
Dudkowiak, Robert Uniwersytecki Szpital Kliniczny Wrocław
Ke˛dzierska, Lidia SPSK 2 PUM w Szczecinie Szczecin
Kempin´ski, Radosław Uniwersytecki Szpital Kliniczny Wrocław Wrocław
Malewski, Waldemar NZOZ Termedica Poznan´
Mamos, Arkadiusz NZOZ Med-Gastr Ło´dz´
Mazurek, Tadusz Centrum Medyczne Medicor Rzeszo´w
Mularczyk, Aldona Specjalistyczna Praktyka Lekarska Katowice
Pilecka, Dorota SPWSZ Szczecin Szczecin
Piotrowski, Wojciech Centrum Medyczne Poradnia Gastrologiczna Ło´dz´
Walentek, Tomasz Szpital Specjalistyczny 1 Bytom
Kosik-Warzyn´ska, Romana SPWSZ w Szczecinie Szczecin
Wojnarowska, Renata Klinika Gastroenterologii USK nr 1 Ło´dz´
Markowski, Adam Humana Media Omeda Białystok
Romatowski, Jacek NZOZ Specjalistyczne Centrun Gastrologii
GASTROMED
Białystok
Tomecki, Roman Przychodnia Fundacji Gastroenterologicznej Warszawa
Wierzbicka, Katarzyna SPZOZ Szpital Bielan´ski Warszawa
Wis´niowski, Marek Centrum Medyczne Medyk Rzeszo´w
Baluta, Małgorzata Centrum Medyczne Da˛browa - Da˛bro´wka Gdynia
Detka-Kowalska, Iga Oddział Gastroenterologiczny Szpital
Specjalistyczny
Kon´skie
Drobin´ska, Anna Klinika Gastroenterologii Gdan´sk
Fra˛czek, Grzegorz Centrum Medyczne Staro´wka Sokoło´w Podlaski
Janiak, Maria Klinika Gastroenterologii I Hepatologii Gdan´sk
Jasin´ski, Bolesław Klinika Gastroenterologii i Hepatologii/Gabinet
Prywatny
Wojkowice
Jastrze˛bska, Marta Oddział Gastroenterologiczny Szpital
Specjalistyczny im. S´w. Łukasza
Kon´skie
Kaczmarzyk, Paweł Szpital Kielecki s´w. Aleksandra Sp. z o.o. Kielce
Krawczyk, Marek Szpital Miejski Tychy
Krela-Kaz´mierczak, Iwona Szpital Kliniczny UM Poznan´
Latos, Wojciech Gabinet Gliwice
Łykowska-Szuber, Liliana Szpital Kliniczny z przychodnia im. H.S´wie˛cickiego
UM
Poznan´
Małuch, Piotr Specjalistyczna Praktyka Da˛browa Go´rnicza
Penpicki, Andrzej NZOZ GASTROMED Białystok
S´wia˛tkowski, Tomasz Przychodnia Specjalistyczna Ke˛dzierzyn - Koz´le
Wo´jtowicz, Henryk Przychodnia Sucholeska Suchy Las
Stro´zik, Agnieszka Gabinet Internistyczny Cze˛stochowa
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Country Principal investigator Institution name City
Augustyn, Monika Indywidualna Praktyka Lekarska Krako´w
Barczyk, Wojciech 105 Szpital Wojskowy SPZOZZ_ary Z_ary
Jonas, Maurycy Spo´łdzielnia Pracy Specjalisto´w Rentgenologo´w Warszawa
Łapin´ski, Janusz Centrum Gastrologiczno Hepatologiczne Wrocław
Majowski, Jarosław Centrum Medyczne Medita Jelenia Go´ra
Worobiec, Jacek Specjalistyczna Poradnia Lekarska i Szpital CDT
MEDICUS
Lubin
Orłowski, Marcin Przychodnia Lekarska Nowy Chełm Gdan´sk
Was´ko-Czopnik, Dorota USK Wrocław Wrocław
Klincewicz, Beata Szpital Kliniczny im. Karola Jonschera Uniwersytetu
Medycznego im. Karola Marcinkowskiego w
Poznaniu
Poznan´
Rydzewska, Graz_yna CSK MSW 1 Warszawa
Wyszkowski, Mariusz Zespo´ł Przychodni Specjalistycznych PRIMA Warszawa
Maciejewska, Katarzyna CSK MSWiA Warszawa
Kaniewska, Magdalena Szpital MSWiA Warszawa
Sweden Bresso, Francesca Karolinska University Hospital Stockholm
Halfvarson, Jonas O¨rebro University Hospital O¨rebro
Sangfelt, Per Uppsala University Hospital Uppsala
Hjortswang, Henrik Linko¨ping University Hospital Linko¨ping
Hertervig, Erik Ska˚ne University Hospital Lund
Eberhardson, Michael Danderyds sjukhus Stockholm
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